Exhibit 10.11
LICENSE AGREEMENT
EFFECTIVE ON THE 28 DAY OF APRIL, 2003
(THE "EFFECTIVE DATE")
BY AND BETWEEN:
THE UNIVERSITY OF CHICAGO
OPERATOR OF ARGONNE NATIONAL LABORATORY
UNDER ITS U. S. DEPARTMENT OF ENERGY CONTRACT NO. W-31-109-ENG-38
(LICENSOR)
&
ADVANCED LIFE SCIENCES, INC.
(LICENSEE)
IPA0322
Page 1 of 14
The Parties to this Agreement are The University of Chicago, as Operator
of ARGONNE NATIONAL LABORATORY ("Licensor") under its U.S. Department of Energy
("DOE") Contract No. W-31-109-ENG-38 (the "DOE Contract") and ADVANCED LIFE
SCIENCES, INC. ("Licensee"), a company organized under the laws of Illinois,
whose business address is 0000 Xxxxxxxxxxxxxx Xxxxx Xxxxxxxxx, XX 00000.
1. BACKGROUND
1.1 Certain inventions ANL-IN-99-019 & ANL-IN-00-019 entitled "A
Fibril-Blocking Peptide, A Method for Preventing Fibril Formation" (the
"Inventions") were conceived of or first reduced to practice as subject
inventions in the performance of work by the Licensor under the DOE Contract.
Pursuant to the terms of the DOE Contract and existing laws of the U.S.,
Licensor has acquired rights in and to said Invention.
1.2 Licensee desires to acquire rights in and to said Inventions for drug
development. Licensor is willing to grant Licensee certain rights to such
Inventions to enable said Inventions to be tested and utilized to the fullest
extent possible so as to provide benefit to the U.S. economy and the general
public.
2. DEFINITIONS
2.1 Licensed Patent shall mean all patent applications, patents of issue,
addition, reissue, reexamination or extensions of the foregoing related to the
Inventions as described in Exhibit A, provided Licensor is the owner thereof.
2.2 Licensed Products means any and all products made, used or sold by
Licensee within the scope of one or more claims of the Licensed Patent.
2.3 A Sale of Licensed Products occurs when a Licensed Product is provided
to another party for other than evaluation purposes.
2.4 Net Sales shall mean the total amounts invoiced to purchasers during the
accounting period in question for Licensed Products sold by Licensee less
allowances for returns of Licensed Products, discounts, rebates, commissions,
freight, and taxes on Licensed Products. Net Sales in the case of Licensed
Products used or transferred shall mean the fair market value of Licensed
Products as if they were sold to an unrelated third party.
2.5 Field of Use shall mean prevention of protein aggregation.
Page 2 of 14
3. GRANT
3.1 Subject to the terms and conditions of this License Agreement, Licensor
hereby grants to Licensee, the exclusive right and license in the Licensed
Patent, with the right to further sublicense, to make, have made, use, and sell,
have sold Licensed Products in the United States, its territories, and
possessions in the Field of Use, subject to the U.S. Government license shown
below.
3.2 The rights and licenses granted in Article 3 shall be subject to the
following limited license granted by Licensor to the U. S. Government:
The U.S. Government is granted for itself and others acting on its
behalf a paid-up, non-exclusive, irrevocable worldwide license in the
Licensed Patent to practice or have practices by or on behalf of the
U.S. Government the Licensed Patent. The U.S. government has certain
other rights under 35 USC 200 et. Seq. and applicable regulations.
NEITHER THE UNITED STATES NOR THE U. S. DEPARTMENT OF ENERGY, NOR ANY
OF THEIR EMPLOYEES, MAKES ANY WARRANTY, EXPRESS OR IMPLIED, OR ASSUMES
ANY LEGAL LIABILITY OR RESPONSIBILITY FOR THE ACCURACY, COMPLETENESS,
OR USEFULNESS OF ANY INFORMATION, APPARATUS, PRODUCT, OR PROCESS
DISCLOSED, OR REPRESENTS THAT ITS USE WOULD NOT INFRINGE PRIVATELY
OWNED RIGHTS.
3.3 Licensee acknowledges that Licensor retains ownership of and title to
the Licensed Patent and Licensee agrees not to sell, lien, encumber or otherwise
dispose of the Licensed Patent except as expressly provided in this Agreement.
Licensee further acknowledges that this Agreement provides no rights to
Licensee, either expressed or implied, to any other intellectual property rights
owned by Licensor or the U. S. Government.
3.4 Any sublicense granted by Licensee shall include all of the rights and
obligations due the Licensor and the U.S. government that are contained herein.
In particular, but without implied limitation, any sublicense granted by
Licensee is subject to the license to the U.S. Government and the rights
retained by Licensor.
4. U.S. COMPETITIVENESS
Licensee agrees that any Licensed Product for use or sale in the United States
shall be manufactured substantially in the United States.
5. ROYALTIES AND COMMERCIALIZATION PLAN
5.1 In consideration of the rights and licenses granted herein, Licensee
agrees to the provisions of Exhibit B and Exhibit C attached hereto and hereby
incorporated into this Agreement
Page 3 of 14
5.2 No royalties shall be owed on any Licensed Product produced for or under
any Federal governmental agency contract pursuant to the DOE nonexclusive
license for Federal governmental purposes, but only to the extent the Federal
government received a discount upon Sale of a Licensed Product which discount is
equivalent to or greater than the amount of any such royalty that would
otherwise be due. Any sales for Federal Government purposes will be reported as
defined in Exhibit D - Report Schedule and Form.
5.3 Upon termination of this Agreement for any reason whatsoever, any
royalties that remain unpaid shall be promptly reported and paid to Licensor
within thirty (30) days of any such termination.
6. RECORDS AND REPORTS
6.1 Licensee agrees to keep adequate and sufficiently detailed records of
sales of Licensed Products to enable royalties payable hereunder to be
determined and to provide such records for inspection by authorized
representatives of Licensor at any time upon reasonable advance notice during
the regular business hours of Licensee. Licensee agrees that any additional
records of Licensee, as Licensor may reasonably determine are necessary to
verify the above records, shall also be provided to Licensor for inspection.
6.2 Within thirty (30) calendar days after the close of each calendar year
during the term of this Agreement (i.e. by January 3l) in which a Sale of a
Licensed Product occurs, Licensee will furnish Licensor a written report as
outlined in Exhibit D providing: (a) the amount of all Net Sales during the
preceding calendar year period of Licensed Products; (b) the amount of royalties
due for the preceding calendar year period pursuant to the provisions of Exhibit
C; and (c) the amount of any Net Sales for U.S. Government purposes.
6.3 License Fees and Royalties as defined in Exhibit C shall accompany
reports as outlined in Exhibit D. All License Fees and Royalties shall be paid
in U.S. Dollars. Should Licensee fail to make any payment to Licensor within the
time period prescribed for such payment, then the unpaid amount shall bear
interest at the rate of one and one-half percent (1.5%) per month or, if less,
the greatest amount permitted by law, from the date when payment was due until
payment in full, with interest, is made.
7. DUE DILIGENCE
Licensee will proceed diligently to test, manufacture, and sell Licensed
Products. Licensee will market Licensed Products diligently within a reasonable
time after this Agreement is executed. Licensee must demonstrate a continuing
effort to test and market Licensed Products. If Licensee is does not perform the
schedule and conditions set forth in Exhibit B, Licensor may terminate this
Agreement.
Page 4 of 14
8. INFRINGEMENT BY THIRD PARTIES
Licensee shall give notice to Licensor of any discovered third party
infringement of the rights granted hereunder of which Licensee has actual
knowledge. Licensor, at Licensor's sole discretion, may attempt to xxxxx such
infringement in whatever reasonable manner it determines.
9. REPRESENTATIONS AND WARRANTIES
9.1 Licensor represents and warranties that Licensor has the right to grant
the rights and licenses granted herein.
9.2 Nothing in this Agreement will be interpreted as:
a. A warranty or representation by Licensor as to the validity or
scope of any of Licensor's rights in Licensed Patents; or
b. A warranty or representation that anything made, used, sold, or
otherwise disposed of under any license granted in this Agreement
is or will be free from infringement of patents or copyrights of
third parties; or
c. Any obligation to bring suit against a third party for copyright
infringement; or
d. Conferring by implication, estoppel, or otherwise any license or
rights under any patents or copyrights of Licensor other than as
defined in this Agreement, regardless whether such patents or such
copyrights are dominant or subordinate to the rights granted
hereunder; or
e. An obligation to furnish any know-how or improvements not
specifically provided in this Agreement.
9.3 Licensor represents and warranties that Licensor has no actual knowledge
of any claims of infringement filed against Licensor for practicing the Licensed
Patents.
10. EXPORT CONTROL
LICENSEE ACKNOWLEDGES THAT THE EXPORT OF ANY MATERIALS AND/OR TECHNICAL DATA
FROM THE UNITED STATES MAY REQUIRE SOME FORM OF EXPORT CONTROL LICENSE FROM THE
U.S. GOVERNMENT. FAILURE TO OBTAIN ANY REQUIRED EXPORT LICENSES BY LICENSEE MAY
RESULT IN LICENSEE SUBJECTING ITSELF TO CRIMINAL LIABILITY UNDER U.S. LAWS.
Page 5 of 14
11. DISCLAIMER
11.1 NEITHER LICENSOR, THE DOE, NOR PERSONS ACTING ON THEIR BEHALF MAKE ANY
WARRANTY, EXPRESS OR IMPLIED: (1) WITH RESPECT TO THE MERCHANTABILITY, ACCURACY,
COMPLETENESS, OR USEFULNESS OF ANY SERVICES, MATERIALS, OR INFORMATION FURNISHED
HEREUNDER; (2) THAT THE USE OF ANY SUCH SERVICES, MATERIALS, OR INFORMATION WILL
NOT INFRINGE PRIVATELY OWNED RIGHTS; (3) THAT THE SERVICES, MATERIALS, OR
INFORMATION FURNISHED HEREUNDER WILL NOT RESULT IN INJURY OR DAMAGE WHEN USED
FOR ANY PURPOSE; OR (4) THAT THE SERVICES, MATERIALS, OR INFORMATION FURNISHED
HEREUNDER WILL ACCOMPLISH THE INTENDED RESULTS OR ARE SAFE FOR ANY PURPOSE,
INCLUDING THE INTENDED OR PARTICULAR PURPOSE. FURTHERMORE, LICENSOR AND THE DOE
HEREBY SPECIFICALLY DISCLAIM ANY AND ALL WARRANTIES, EXPRESS OR IMPLIED, FOR ANY
MATERIALS MANUFACTURED, USED, OR SOLD BY LICENSEE. NEITHER LICENSOR NOR THE DOE
SHALL BE LIABLE FOR CONSEQUENTIAL OR INCIDENTAL DAMAGES IN ANY EVENT.
11.2 Licensee agrees to assert a disclaimer of warranties for the benefit of
Licensor and the U. S. Government, to the maximum extent authorized by the
Uniform Commercial Code, in all U.S. sales of the Licensed Product.
12. PRODUCT LIABILITY
Except for any liability resulting from any negligent act or omission of the
U. S. Government or Licensor, Licensee indemnifies the U. S. Government and
Licensor, and their officers, employees, and agents, for all damages, costs, and
expenses, including attorneys' fees, arising from personal injury or property
damage to third parties occurring as a result of the commercialization and
utilization of the Licensed Products by Licensee, including but not limited to,
the making, using, selling, or exporting of materials, processes, or services
derived therefrom. This indemnification shall include, but not be limited to,
indemnification for any product liability resulting from the commercialization
and utilization of Licensed Products by Licensee. The indemnity set forth in
this Article 12 shall apply only if Licensee shall have been informed as soon
and as completely as practical by Licensor and/or the U. S. Government of the
action alleging such claim and shall have been given an opportunity, to the
maximum extent afforded by applicable laws, rules, or regulations, to
participate in and control its defense, and Licensor and/or the U. S. Government
shall have provided reasonably available information and reasonable assistance
requested by Licensee. No settlement for which Licensee shall be responsible
shall be made without Licensee's consent unless required by final decree of a
court of competent jurisdiction.
Page 6 of 14
13. TERM OF AGREEMENT AND EARLY TERMINATION
13.1 Unless previously terminated by operation of law or by acts of the
Parties under this Agreement, this Agreement shall be in full force and effect
from the effective date thereof and shall remain in effect for the term of the
intellectual property rights in the Licensed Patents.
13.2 A Party shall have the right to terminate this Agreement (without
judicial resolution) upon notice to the other Party after a breach of any
provision by the other Party has gone uncorrected for sixty (60) days after the
other Party has been notified of such breach by the terminating Party.
13.3 Licensee shall have the right to terminate this Agreement upon thirty
(30) days written notice if Licensed Product fails to achieve appropriate
industry testing results at any testing stage. In such event, and included with
such termination notice, Licensee will provide without restriction all testing
results to Licensor.
13.4 Any termination pursuant to this Article shall not relieve Licensee of
any obligation or liability accrued hereunder prior to the effective date of
such termination.
14. RIGHTS OF PARTIES AFTER TERMINATION
14.1 Neither Party shall be relieved of any obligation or liability under
this Agreement arising from any act or omission committed prior to the effective
date of termination. All license rights granted under this Agreement shall
terminate as of the effective date of any termination.
14.2 Upon termination of this License Agreement by either Licensor or
Licensee, Licensee shall provide Licensor with a written list of all Licensed
Products in the process of being sold. On any termination, Licensee shall duly
account to Licensor and transfer all rights to which Licensor may be entitled
under this Agreement.
14.3 If this Agreement is terminated, Licensor will automatically succeed to
all rights of Licensee arising from sublicenses granted under this Agreement.
Any sublicensee who is not in default of the terms and conditions of its
sublicense agreement with Licensee may make a written request to continue such
sublicense agreement as a license agreement with Licensor, which request will
not be unreasonably denied.
14.4 The rights and remedies granted herein, and any other rights or remedies
which the Parties may have, either at law or in equity, are cumulative and not
exclusive of others.
15. PATENT PROSECUTION
It is understood and agreed that Licensor shall manage and control the
prosecution of patent applications. Licensee agrees that for each Invention
filed and prosecuted in the U.S. Patent and Trademark Office, Licensee shall
directly reimburse Licensor's patent counsel, no later than thirty (30) days
after billing, costs incurred after the Effective Date associated with drafting,
filing,
Page 7 of 14
prosecution, issuance and maintenance. Licensor agrees to instruct its patent
counsel to provide Licensee copies of documents filed and received in the filing
and prosecution of patents filed, and shall afford Licensee an opportunity to
comment thereon. Licensee agrees to assist in the prosecution efforts by
providing any data and test results, if needed.
16. ASSIGNABILITY
The Parties agree that the Licensor, at its sole discretion, may immediately
terminate this Agreement upon any attempt by Licensee to transfer its interest
in whole or in part in this Agreement to any third party without the written
permission of the Licensor, except for a transfer in connection with a sale or
transfer of all or substantially all of the relevant business and assets of
Licensee to which this Agreement relates to a third party who agrees in writing
to be bound by the provisions of this Agreement. This Agreement shall insure to
the benefit of and shall be binding upon the Parties and their successors,
transferees and permitted assigns, and the name of a Party appearing herein
shall be deemed to include the names of such Party's successors, transferees and
permitted assigns to the extent necessary to carry out the intent of and
performance of the obligations of the Parties under this Agreement.
17. MARKING
Licensee agrees to affix appropriate markings of the Licensed Patent upon or in
association with Licensee's Licensed Products.
18. FORCE MAJEURE
No failure or omission by Licensor or by Licensee in the performance of any
obligation under this Agreement shall be deemed a breach of this Agreement or
create any liability if the same shall arise from: acts of God; acts or
omissions of any government or agency thereof; compliance with rules,
regulations, or orders of any governmental authority; fire; storm; flood;
earthquake; accident; acts of the public enemy; war; rebellion; insurrection;
riot; sabotage; invasion; quarantine; restriction; or failures or delays in
transportation.
19. PUBLICATION AND PUBLICITY
19.1 The parties intend to jointly publish the results of research studies.
Each party agrees to secure pre-publication approval, including appropriate
patent review, from the other Party for any publication which mentions the other
party or discloses research study results, which approval shall not be
unreasonably withheld or delayed beyond thirty (30) days.
19.2 Nothing contained in this Agreement shall be construed as conferring any
right to use in advertising, publicity, or other promotional activities any
name, tradename, trademark, or other designation of Licensor or Licensee or of
the U. S. Department of Energy or the U. S. Government, or any of their
employees or officers, and any contraction, abbreviation, or simulation of any
of the foregoing.
Page 8 of 14
20. NOTICES
20.1 All notices and reports shall be addressed to the Parties as follows:
If to Licensor:
Director
Office of Technology Transfer Facsimile No. 000-000-0000
Argonne National Laboratory Verify No. 000-000-0000
0000 X. Xxxx Xxxxxx
Xxxxxxx, XX 00000-0000
If to Licensee:
Xxx Xxxxxx Facsimile No. 000-000-0000
Advanced Life Sciences Verify No. 000-000-0000
0000 Xxxxxxxxxxxxxx Xxxxx
Xxxxxxxxx, XX 00000
20.2 Any notice, report or any other communication required or permitted to
be given by any Party to any other Party by this Agreement shall be in writing
and either (a) served personally on the other Party, (b) sent by express,
registered or certified first-class mail, postage prepaid, addressed to the
other Party at its address as indicated above, or to such other address as shall
have previously furnished to the other Party by proper notice, (c) delivered by
commercial courier to the other Party, or (d) sent by facsimile to the other
Party at its facsimile number indicated above or to such other facsimile number
as the Party shall have previously furnished to the other party by proper
notice, with machine confirmation of transmission. Such notice shall be
effective when received by the receiving Party.
21. WAIVERS
No provision of this Agreement is deemed waived and no breach excused unless
such waiver or consent is made in writing and signed by the Party to have waived
or consented. Failure on the part of any Party to exercise or enforce any right
under this Agreement will not be a waiver of any right, or operate to bar the
enforcement or exercise of the right at any time thereafter.
22. ENTIRE AGREEMENT AND MODIFICATIONS
It is expressly understood and agreed by the Parties that this instrument
contains the entire agreement between the Parties with respect to the subject
matter hereof and that all prior representations, warranties, or agreements
relating hereto have been merged into this document and are thus superseded in
totality by this Agreement. This Agreement may be amended or modified only by a
written instrument signed by the duly authorized representatives of the Parties.
Page 9 of 14
23. HEADINGS
The headings for the sections set forth in this Agreement are strictly for the
convenience of the Parties and shall not be used in any way to restrict the
meaning or interpretation of the substantive language of this Agreement.
24. GENERAL CONSIDERATIONS
24.1 The Parties will attempt to jointly resolve any disputes arising from
this Agreement. Such joint resolution may include non-binding arbitration. If
the Parties are unable to resolve a dispute within a reasonable time, then any
Party may commence proceedings in a court of competent jurisdiction.
24.2 If any provisions of this Agreement are held to be invalid, illegal, or
unenforceable in any respect, that invalidity, illegality, or unenforceability
will not affect any other provisions of the Agreement. This Agreement will be
construed as if the invalid, illegal, or unenforceable revision were never in
this Agreement.
24.3 Licensor will release information concerning this Agreement if required
by law.
IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly
executed in their respective names by their duly authorized representatives.
THE UNIVERSITY OF CHICAGO, AS OPERATOR OF ADVANCED LIFE SCIENCES, INC.
ARGONNE NATIONAL LABORATORY
By: /s/ [ILLEGIBLE] By: /s/ Xxxxxxx X. Xxxxxx
----------------------------------- -----------------------------------
Name Xxxxxx X. Xxxxxxxxx Name: XXXXXXX X. XXXXXX
----------------------------------- -----------------------------------
(Typed) (Typed)
Title: Manager, ANL Procurement Title: CHIEF EXECUTIVE OFFICER
----------------------------------- -----------------------------------
Date: 4/25/03 Date: 4/28/03
----------------------------------- -----------------------------------
Page 10 of 14
EXHIBIT A - INTELLECTUAL PROPERTY
LICENSED PATENT includes the following Inventions:
ANL-IN-99-019 & ANL-IN-00-019 filed as USPTO application no. 09/712,819 entitled
"A Fibril-Blocking Peptide, A Method for Preventing Fibril Formation"
Page 11 of 14
EXHIBIT B - DILIGENCE IN SALE OF LICENSED PRODUCTS
NOTICE
THIS EXHIBIT B CONTAINS FINANCIAL AND COMMERCIAL INFORMATION DEEMED BUSINESS
CONFIDENTIAL. THE PARTIES AGREE NOT TO USE OR TO DISCLOSE THE TERMS OF THIS
EXHIBIT TO ANY THIRD PARTY WITHOUT THE EXPRESS WRITTEN CONSENT OF THE OTHER
PARTY, EXCEPT AS NECESSARY TO ENABLE THE PARTIES TO PERFORM UNDER THIS AGREEMENT
OR AS MAY BE REQUIRED BY LICENSOR'S CONTRACT WITH THE U.S. DEPARTMENT OF ENERGY.
DUE DILIGENCE REQUIREMENT:
Licensee will proceed diligently to test, manufacture, and sell Licensed
Products. Licensee will market Licensed Products diligently within a reasonable
time after this Agreement is executed. Licensee must demonstrate a continuing
effort to test and market Licensed Products. These requirements will be
demonstrated by:
a) Licensee will provide a minimum of 0.5 Full-Time-Equivalent (FTE) amount of
technical effort dedicated to the Licensed Patent and Licensed Product until
completion of Phase 1 clinical trials. This requirement may also be satisfied by
sublicensing the Licensed Patent to a third party who commits to provide an
equivalent or greater FTE amount of effort.
b) Licensee will provide annual progress reports on its clinical trial
efforts, as well as its marketing efforts, on an annual basis (due January 30 of
each year).
If Licensee is does not perform conditions set forth in this Exhibit B, Licensor
may terminate this Agreement under Article 13 of the Agreement.
Page 12 of 14
EXHIBIT C - LICENSE FEES AND ROYALTIES
NOTICE
THIS EXHIBIT C CONTAINS FINANCIAL AND COMMERCIAL INFORMATION DEEMED BUSINESS
CONFIDENTIAL. THE PARTIES AGREE NOT TO USE OR TO DISCLOSE THE TERMS OF THIS
EXHIBIT TO ANY THIRD PARTY WITHOUT THE EXPRESS WRITTEN CONSENT OF THE OTHER
PARTY, EXCEPT AS NECESSARY TO ENABLE THE PARTIES TO PERFORM UNDER THIS AGREEMENT
OR AS MAY BE REQUIRED BY LICENSOR'S CONTRACT WITH THE U.S. DEPARTMENT OF ENERGY.
1. ROYALTIES: Licensee will pay Licensor a royalty of four percent (4%) of
the Net Sales of Licensed Products annually for the life of this Agreement,
within thirty (30) days of the end of the calendar year (December 31).
2. ROYALTIES AND FEES UNDER SUBLICENSES:
a) Licensee will provide Licensor with a copy of each sublicense
entered into with a third party within thirty (30) days of execution.
All sublicense royalties and fees due Licensor shall be paid to
Licensor by Licensee, whether actually received or not from the
sublicense. All sublicense royalties and fees due Licensor shall be
paid within thirty (30) days of the end of the calendar year (December
31) annually for the life of the Agreement.
b) Licensee will pay Licensor a royalty of four percent (4%) of the
Net Sales of Licensed Products from sublicenses issued by Licensee
under this Agreement, or twenty percent (20%) of the sublicense
royalties received by Licensee, whichever is greater.
c) Licensee will pay Licensor ten percent (10%) of the total fees or
payments received by Licensee from sublicenses issued by Licensee under
this Agreement, including without implied limitation, benchmark and
milestone payments.
Page 13 of 14
EXHIBIT D - REPORT SCHEDULE AND FORM
NOTICE
THIS EXHIBIT D CONTAINS FINANCIAL AND COMMERCIAL INFORMATION DEEMED BUSINESS
CONFIDENTIAL THE PARTIES AGREE NOT TO USE OR TO DISCLOSE THE TERMS OF THIS
EXHIBIT TO ANY THIRD PARTY WITHOUT THE EXPRESS WRITTEN CONSENT OF THE OTHER
PARTY, EXCEPT AS NECESSARY TO ENABLE THE PARTIES TO PERFORM UNDER THIS AGREEMENT
OR AS MAY BE REQUIRED BY LICENSOR'S CONTRACT WITH THE U.S. DEPARTMENT OF ENERGY.
Starting January 30, 2003, and on an annual basis thereafter (due January 30 of
each year), Licensee will submit a report to Licensor reporting the information
shown below for the prior twelve (12) month period.
REPORT DATE:
REPORTING PERIOD:
LICENSEE NAME: ADVANCED LIFE SCIENCES, INC.
LICENSE NUMBER: IPA0322
EARNED ROYALTIES PAID FOR THE REPORTING PERIOD: US $
SALES AND ROYALTIES:
--------------------------------------------------------------------
ROYALTIES
DESCRIPTION OF UNITS NET SALES DUE
LICENSED PRODUCTS SOLD US $ US $
--------------------------------------------------------------------
U.S. GOVERNMENT SALES:
U.S. GOVERNMENT AGENCY: _____________ CONTRACT NO.
HOW THE BENEFIT OF THE ROYALTY-FREE SALE WAS PASSED TO THE U.S. GOVERNMENT:
MARKETING EFFORTS:
HOW THE LICENSED PRODUCTS WERE TESTED AND MARKETED:
Page 14 of 14
